Creating a registry for personalized medicine in urological cancer patients using circulating tumor DNA
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
This study is trying to see if testing blood and urine for tumor DNA can help doctors better diagnose and monitor urological cancers like prostate and bladder cancer in patients who have had surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Yonsei University Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT04197414 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the usefulness of circulating tumor DNA (ctDNA) in the detection and monitoring of urological malignancies, including prostate, renal cell, bladder, and ureter cancers, within the Korean population. By analyzing ctDNA from plasma and urine samples, the study seeks to build a comprehensive database that can enhance diagnosis, track disease progression, and assess therapeutic responses. The research will focus on patients who have undergone surgeries for these cancers at Severance Hospital from December 2019 to November 2029, with the goal of developing an optimized ctDNA platform for personalized medicine.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with urological malignancies who have undergone surgery at Severance Hospital and consented to participate.
Not a fit: Patients who do not have urological malignancies or those who do not agree to participate in the study will not benefit.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and personalized treatment strategies for patients with urological malignancies.
How similar studies have performed: While the use of circulating tumor DNA in urological malignancies is still emerging, similar approaches in other cancer types have shown promising results, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Patients diagnosed as urological malignances (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) * 2\. Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2019.12 and 2029.11 * 3\. Those who agree to give permission to use their human source information - 4. Those who agree with this study Exclusion Criteria: * 1\. Those who do not agree with this study * 2\. Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making
Where this trial is running
Seoul
- Department of Urology, Urological Science Institute, Yonsei University, Colleage of Medicine — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Won Sik Ham
- Email: uroham@yuhs.ac
- Phone: 02-2228-2310
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.